Image Credit: Canva (representational purpose only)
Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.
The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.
Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."
Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.
Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.
Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.
Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog
High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.
Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.
According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.
The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.
Also Read: Mysterious Fog Is Making Americans Sick
These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.
Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.
On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.
The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.
The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.
In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.
Credit: PIB
India’s Union Ministry of Health and Family Welfare has introduced "healthy lifestyle and mental wellness" as two key priority areas at the First Health Working Group (HWG) Meeting under the BRICS framework for the year 2026 in New Delhi.
HWG is a key platform for advancing cooperation in public health, said Punya Salila Srivastava, the Union Health Secretary while chairing the meeting.
She noted that as the BRICS Chair for 2026, India is guided by the overarching theme “Building for Resilience, Innovation, Cooperation and Sustainability”, reflecting a people-centric and humanity-first approach.
The theme underscores India’s commitment to strengthening collaborative frameworks that are responsive, inclusive, and future-ready.
While reaffirming commitment to existing priorities, the Union Health Secretary also proposed two new priority areas under India’s Chairship:

In addition, under the country’s Chairship, Srivastava said that the HWG aims to:
Srivastava hailed the BRICS Health Working Group meetings for having paved the way for collaboration on pressing health challenges in the recent year. She said that the HWG made efforts towards tackle communicable and non-communicable diseases, enhancing health systems, as improving access to affordable medicines.
“These efforts have further strengthened cooperation in pandemic preparedness, health technology innovation, and the promotion of Universal Health Coverage,” Srivastava said.
The meeting also deliberated on the nine priority areas, which include:
The meeting brought together senior health officials, technical experts, and delegates from BRICS member countries—Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, the United Arab Emirates, and Indonesia to deliberate on priority areas of cooperation in public health.
The global experts welcomed India’s leadership and the shared theme of building resilience through innovation, cooperation, and sustainability.
They also emphasized
Credit: iStock
Weeks after the US Food and Drug Administration (FDA) approved Eli Lilly's Orforglipron, marketed as Foundayo, the regulator is asking Eli Lilly to share more safety data on its first oral pill for weight loss.
The FDA has also sought more information on whether Foundayo could be linked to liver and heart problems, according to the FDA's new drug application approval letter.
Foundayo won FDA approval this month under the Commissioner’s National Priority Voucher, a pilot program intended to fast-track drug reviews.
In the approval letter, the FDA noted that the currently available data do not fully clarify several potential risks, including
However, the FDA asking for more data “doesn’t mean a safety problem has been found. It means they want more definitive long-term data,” Dr. Christopher McGowan, a North Carolina-based gastroenterologist, told NBC News.
“With orforglipron, it’s a newer, non-peptide version of a GLP-1, so we don’t yet have the same depth of safety data as the injectables,” he added.
Also read: Eye Drops: US FDA Recalls Over 3 Million Products Over Safety Concerns
Further, the agency also requires Lilly to run a series of new studies, including a registry tracking children with obesity who use weight loss drugs and a pregnancy registry to monitor outcomes.
In a statement, the US FDA said that "Foundayo has been approved for use in combination with a reduced-calorie diet and increased physical activity. The pill is targeted to reduce excess body weight and maintain weight reduction for the long term in adults with obesity or overweight".
The US FDA approved Foundayo after two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight showed benefit.

In these trials, 72 weeks of treatment with Foundayo, in combination with a reduced-calorie diet and increased physical activity, resulted in a statistically significant and clinically meaningful reduction in body weight.
Foundayo’s approval comes after the US FDA in December last year approved Novo Nordisk’s Wegovy pill — the first-ever GLP-1 pill for weight loss. The Danish drugmaker rolled out the pill in January this year.
Novo Nordisk was also the first to launch oral GLP 1 Rybelsus to treat type 2 diabetes. It was approved by the US FDA in September 2019.
Also read: US FDA Recalls China-made Cough Drops And Throat Lozenges
The FDA’s post-approval requirements are routine and consistent with the agency’s approach to ongoing safety reviews of newly approved drugs, according to a Lilly spokesperson, NBC News reported.
“Patient safety is Lilly’s top priority, and we actively monitor, evaluate, and report safety information for all our medicines,” the spokesperson said.
Meanwhile, Lilly has started selling the drug from April 6 through its direct-to-consumer platform LillyDirect at $149 per month for the lowest dose for self-pay customers, on par with Novo's pill. "Shortly after,” it will be available through retail pharmacies and telehealth providers in the US, as per Lilly.
Credit: Instagram
Indian pediatrician Dr Sivaranjani Santosh has resigned from the Indian Academy of Paediatrics (IAP) over lack of support, alleged threats, and false allegations, amid an ongoing controversy over the marketing of oral rehydration solution (ORS)-like products.
The Hyderabad-based pediatrician has been a key public health figure who fought for eight long years to stop FSSAI—the country’s apex food regulator—from using the term ORS by brands of fruit-based, non-carbonated beverages, in October last year.
She again voiced her concerns with the IAP when the manufacturer in January 2026 launched a rebranded version, ERZL for everyday hydration.
Dr Santosh opposed the move and called out on IAP to prevent the launch, saying it closely resembled ORS and could mislead people, especially those in rural areas.
However, she did not receive any support from the IAP, and no action was taken. Rather, she received a legal notice from Kenvue over her comments. Kenvue Inc. is an American consumer health company and was formerly the Consumer Healthcare division of Johnson & Johnson.
The notice from Kenvue claimed that Dr Santosh has been maligning the names of ORSL and ERZL for her "own commercial benefits" and for "increasing the number of followers" on her page.
Deeply saddened by the leadership at the IAP, which she alleged is supporting Kenvue, Dr Santosh resigned. She now vouches to fight alone.
“I thought enough of this toxicity. I'll fight it alone. All this while, if I could fight it alone, why can't I do it?” she told HealthandMe.
Speaking to HealthandMe, the pediatrician narrated the ordeal – legal notices from pharmaceutical companies, false accusations of her integrity and character in the last few years.
Dr Santosh has been campaigning that commercial beverages labeled as ORS were often high in sugar and nutritionally different from the World Health Organization (WHO)-recommended Oral Rehydration Solution, a life-saving treatment for dehydration.
Her fight began in 2022, when she filed a Public Interest Litigation (PIL) in the Telangana High Court seeking directions for manufacturers to remove the letters “ORS” from the product name ORSL.
Eight years after the PIL, the Food Safety and Standards Authority of India (FSSAI), in October 2025, banned the use of the ‘ORS' label on beverages — including ORS that did not meet the WHO standards. The regulator deemed such branding to be misleading and a potential health risk, as many products contained excessive amounts of sugar compared to genuine medical ORS.
However, Kenvue launched a rebranded version, ERZL, in January this year. She again opposed and stated: “ERZL is not ORS. And it should not be given to children below two years of age".
Noting that her messages "upset these people”, she faced a backlash, including a legal notice from the company.
According to Dr Santosh, attempts were also made to gather endorsements from pediatricians claiming that sucralose is safe and to submit these to the FSSAI. She publicly criticized the move, calling it “shameful.”
Further, Dr Santosh also voiced out her concerns against IAP for allowing the company to set up a stall with the controversial product at the Pedicon, a major pediatric conference.
When she raised the matters on social media, the company made the statement: “Our products are very scientific. Some people are spreading misinformation and scientific information”.
The pediatrician also claimed to have alerted IAP leadership weeks earlier, warning that the ERZL’s branding could mislead people—especially in rural areas—into confusing it with ORS.
“We are not talking about the educated people who have been following this. We are talking about the ignorant poor people in the villages,” the doctor said.
She further alleged that instead of backing her concerns, sections of the leadership attempted to discredit her.
Following a series of exchanges and growing tensions, she announced her resignation, citing a “toxic environment.”
Dr Santosh said that "parallelly, the leadership was spreading messages to all the people that I am abusive and I'm arrogant." In response, she stated: "If I have to choose between children and IAP, I will choose children".
Amid the controversy, the IAP released a position statement on ORS and electrolyte drinks. The doctor criticised the statement as “ambiguous” and questioned its focus solely on sucralose, alleging a potential conflict of interest.
She added that Kenvue also marketed for "ERZL as the new form of ORSL", which also bypassed the FSSAI and Delhi High Court orders.
What Is The Way Forward?
Noting that her battle will continue against ERZL, Dr Santosh said she will continue advocating for child health issues in India
"I'm trying to raise awareness about first aid and CPR. I've trained so many people. Now I'm motivated."
The pediatrician also wants to advocate for safer drug formulations, restrictions on over-the-counter medicines, and wider awareness of first aid and CPR.
The list includes paracetamol, which is being sold under various names and doses in the country.
"We want one paracetamol in India".
HealthandMe is trying to reach out to the Indian Academy of Paediatrics (IAP). The copy will be updated once a response is received.
© 2024 Bennett, Coleman & Company Limited